2025

Oral antibodies for prophylactic treatment of enteric infectious diseases

28 January 2025

Antimicrobial resistance (AMR) is a top ten public threat to human health. Immuron is developing innovative colostrum-based oral antibodies to treat infectious diseases without the use of antibiotics.

PJ Daniels Show: Is this the next big opportunity?

21 January 2025

Is this the best opportunity right now? Interview with CEO Steven Lydeamore of Immuron ($IMRN)